Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is an open label, phase IIa trial in subjects with Myelofibrosis
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2020-12-21; most recent amendment 2024-09-10.
Status change: Active, Not Recruiting → Unknown 2024-09-10
Status change: Recruiting → Active, Not Recruiting 2023-05-04
Status change: Not Yet Recruiting → Recruiting 2021-07-28
Trial Details
NCT Number NCT04679870
Lead Sponsor Galecto Biotech AB
Collaborators: OPIS s.r.l
Conditions Myelofibrosis
Enrollment 21 participants
Start Date 2021-06-09
Primary Completion 2023-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-04-03